On the 69th episode of Enterprise AI Innovators, hosts Evan Reiser (CEO and co-founder, Abnormal AI) and Saam Motamedi (General Partner, Greylock Partners) are joined by Greg Meyers, Chief Digital and Technology Officer at Bristol Myers Squibb. Bristol Myers Squibb is one of the top ten pharmaceutical companies, with about 30,000 employees and roughly 45 billion dollars in annual revenue, making specialty medicines in oncology, immunology, and neurology. Greg shares how BMS puts commercially scalable AI products in front of doctors, why a science company had to start thinking like a data company, and how a small-team accelerator de-risks ambitious AI bets in a highly regulated industry. Quick Hits from Greg: On thinking like a data company: &quot;to models, negative results matter as much as positive results.&quot; On running small experimental teams: &quot;making them too small to fail in a public or embarrassing way was really important.&quot; On what really gates AI adoption: &quot;psychology and sociology trump technology every time.&quot; Like what you hear? Leave us a review and subscribe to the show on Apple, Spotify, and YouTube. Enterprise AI Innovators is a show where top technology executives share specific ways AI changes how work gets done in the enterprise. Find more great insights from technology leaders and enterprise software experts at https://www.enterprisesoftware.blog/ Enterprise AI Innovators is produced by Abnormal Studios.

Transforming Cancer Diagnoses and Treatment with Bristol Myers Squibb CDTO Greg Meyers

Enterprise AI Innovators

Hi there, and welcome to Enterprise AI Innovators, a show where top technology executives share how AI is transforming the enterprise. In each episode, guests uncover the real-world applications of AI for improving products and optimizing operations to redefining the customer experience. I'm Evan Reiser, the founder and CEO of Abnormal AI. And I'm Saam Motamedi, a general partner at Greylock Partners. Today we're talking with Greg Meyers, Chief Digital and Technology Officer at Bristol Myers Squibb.

Bristol Myers Squibb is one of the top 10 pharmaceutical companies with about 30,000 employees and roughly $45 billion in annual revenue, making specialty medicines in oncology, immunology, and neurology. Greg runs an organization of several thousand people, which gives him a rare view into how AI is reshaping drug development from the lab to the doctor's office. A few things stuck with me from this conversation. First, BMS is the only pharma company with four commercially scalable AI products in the hands of doctors.

In a year-long lung cancer study across 14 clinical sites, AI Red CT scans doubled the number of newly diagnosed patients and caught 116 new cases. When the average lung cancer patient gets about five years after diagnosis, early diagnosis changes lives. Second, BMS runs an AI accelerator. Six to eight engineers and 12 weeks to answer one question, can AI do X or not? Greg deliberately keeps the teams tiny so they're too small to fail in any public or embarrassing way, which means they can easily throw out the work and start over.

At a big company, permission to fail quietly is the thing that actually unlocks scale. And finally, Greg's advice for activating AI in a tradition-bound industry is to stop asking how a process works and start asking why it works that way.

Transforming Cancer Diagnoses and Treatment with Bristol Myers Squibb CDTO Greg Meyers

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Transforming Cancer Diagnoses and Treatment with Bristol Myers Squibb CDTO Greg Meyers

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.